Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.03
+0.5%
$3.08
$2.12
$5.80
$398.30M1.971.49 million shs1.00 million shs
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
$25.44
$1.23M1.4122,322 shsN/A
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
$15.00
$14.97
$3.06
$15.00
$521.45M1601,442 shs247,800 shs
OASM
Oasmia Pharmaceutical AB (publ)
$0.02
$1.46
$0.94
$5.70
$1.50M0.9698,414 shsN/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+0.50%+8.33%+12.57%+63.16%+63.82%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%-73.80%
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
OASM
Oasmia Pharmaceutical AB (publ)
0.00%0.00%0.00%0.00%-59.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
1.452 of 5 stars
3.51.00.00.02.50.00.0
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$10.14151.68% Upside
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.00
N/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AVEO, OASM, AQST, and ASLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/2/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
5/15/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$57.56M6.95N/AN/A($0.66) per share-6.11
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
$42.29M12.33N/AN/A$1.33 per share11.28
OASM
Oasmia Pharmaceutical AB (publ)
$220K6.82N/AN/A$0.63 per share0.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$44.14M-$0.59N/AN/AN/A-100.02%N/A-50.31%8/5/2025 (Estimated)
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/A-8,454.87%-121.60%N/A
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/A
OASM
Oasmia Pharmaceutical AB (publ)
-$18.95MN/A0.00N/A-8,633.64%-43.94%-28.92%N/A

Latest AVEO, OASM, AQST, and ASLN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.18N/AN/AN/A$11.32 millionN/A
5/12/2025Q1 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
N/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
4.87
4.48
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.94
2.37
2.35
OASM
Oasmia Pharmaceutical AB (publ)
N/A
0.80
0.73
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
16099.33 million91.03 millionOptionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionOptionable
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
11434.76 million33.62 millionOptionable
OASM
Oasmia Pharmaceutical AB (publ)
5774.97 millionN/ANot Optionable

Recent News About These Companies

Double Bond Pharmaceutical International AB (DBPHAb)
Sector-Health Care & Pharmaceuticals
BOEUF Bonesupport Holding AB (publ)
Lipigon Pharmaceuticals AB LPGO
Resurs Holding AB (publ) (RESURS.ST)
QuiaPEG Pharmaceuticals Holding AB QUIA
Newbury Pharmaceuticals AB (NEWBRY)
Lipigon Pharmaceuticals AB (LPGO)
Speqta publ AB (SPEQT)
PRXXF Paradox Interactive AB (publ)
Notice of annual general meeting in Alzinova AB (publ)
Oasmia expands R&D ability with planned laboratory upgrade

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$4.03 +0.02 (+0.50%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$4.00 -0.04 (-0.87%)
As of 04:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 07/8/2025

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

AVEO Pharmaceuticals stock logo

AVEO Pharmaceuticals NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Oasmia Pharmaceutical AB (publ) NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.